z-logo
open-access-imgOpen Access
Decreasing maternal myostatin programs adult offspring bone strength in a mouse model of osteogenesis imperfecta
Author(s) -
Arin K. Oestreich,
William M. Kamp,
Marcus G. McCray,
Stephanie M. Carleton,
Natalia G. Karasseva,
Kristin L. Lenz,
Youngjae Jeong,
Salah A. Daghlas,
Xiaomei Yao,
Yong Wang,
Ferris M. Pfeiffer,
Mark R. Ellersieck,
Laura C. Schulz,
Charlotte L. Phillips
Publication year - 2016
Publication title -
proceedings of the national academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.011
H-Index - 771
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.1607644113
Subject(s) - osteogenesis imperfecta , myostatin , offspring , fetal programming , medicine , endocrinology , pregnancy , biology , muscle hypertrophy , anatomy , genetics
Significance Osteogenesis imperfecta (brittle bone disease) is an incurable genetic disorder. We demonstrate that maternal deficiency of myostatin (a negative regulator of muscle growth) can enhance bone biomechanical strength and integrity in control and osteogenesis imperfecta mouse offspring, using three independent approaches. We provide evidence that bone is responsive to developmental programming and that myostatin can mediate these effects. Embryo transfer experiments show that the effects of maternal myostatin deficiency are conferred by the postimplantation environment. These studies represent a paradigm shift in understanding and treating osteogenesis imperfecta—a shift from believing only genetic and postnatal environmental factors control bone health to the inclusion of prenatal/perinatal developmental programming as a modifiable factor controlling adult bone health.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom